The Woman’s Board of Northwestern Memorial Hospital Pledges $2M to Northwestern Medicine Developmental Therapeutics Institute

THE NORTHWESTERN MEDICINE Developmental Therapeutics Institute (NMDTI) has received a pledge of $2 million from the Woman’s Board of Northwestern Memorial Hospital to support the launch of the NMDTI, the establishment of its first clinics, and critical startup funding to create the Northwestern Medicine Developmental Therapeutics Fellowship Program. The generous gift will enable physician-scientists who have completed their initial training in Internal Medicine and Hematology and/or Oncology to further specialize in the rapidly evolving field of developmental therapeutics.

“With our commitment to the institute, The Woman’s Board is furthering its mission of helping to solidify Northwestern’s position as a preeminent site for cancer research and treatment,” said Laura Davis, President of The Woman’s Board. “With the introduction of crucial Phase I trials, patients in Chicago and the region will have access to novel therapies at Northwestern Medicine and we are delighted that the program will be training the next generation of teachers in developmental therapeutics.”

» Read more

SAVE THE DATE: Sunday, June 1st
21st Annual Cancer Survivors' Celebration Walk & 5K

MAKE PLANS TO walk, run and celebrate the strides being made in cancer treatment and research. Held in Grant Park on National Cancer Survivors Day, this community awareness event brings cancer survivors, families, and friends together with the physicians, scientists, and health professionals who support them for a meaningful, memorable morning.

Activities for the family include a non-competitive walk or chip-timed 5K, a picnic, t-shirts, music and entertainment.

» Read more...
Parsa Named Co-Leader, Translational Research in Solid Tumors Program

ANDREW PARSA, MD, PHD, has been named Co-Leader of the Translational Research in Solid Tumors Program (TRIST) at the Lurie Cancer Center. Parsa, an internationally-renowned neurosurgeon and researcher specializing in complex tumors of the brain and spine, is the Michael J. Marchese Professor and Chair of the Department of Neurological Surgery at the Feinberg School of Medicine.

The overall goal of the TRIST Program is to coordinate and enhance the interactions among researchers in the area of solid cancers at Northwestern University. A highly interactive and productive program, TRIST consists of accomplished faculty conducting translational studies centered on the themes of molecular and cell biology, early diagnosis, prognosis, risk factors, therapeutics and treatment of cancer of the aerodigestive tract, dermatologic, gastrointestinal, genitourinary and neuro-oncologic cancers. Parsa’s skills will complement the expertise of TRIST Program Co-Leader Marcus Peter, PhD.

“As a physician-scientist with a remarkable history of success in translating research into advanced therapeutics, Andy’s accomplishments make him the ideal person to be the clinical Co-Leader of the TRIST program,” said Leonidas Platanias, MD, PhD, Interim Director of the Lurie Cancer Center.

Al B Benson III, MD, who served for two years as the TRIST Program’s previous Co-Leader, is taking on expanded responsibilities in his role as Associate Director for Clinical Investigations. He will Chair the Lurie Cancer Center’s newly created National Clinical Trial Network (NCTN) oversight committee which is charged with overseeing all cooperative clinical trial activities, including the National Comprehensive Cancer Network (NCCN), the new Big Ten Cancer Research Consortium, and all NCI groups. Benson was instrumental in developing the TRIST Program prior to its first review by the NCI in 2013, when it received an “Outstanding” rating.

New Prostate Cancer Test Reduces Need for Biopsies

NORTHWESTERN MEDICINE is the first health care provider in the country to offer a new non-invasive blood test for prostate cancer that is nearly three times more accurate than the current standard prostate-specific antigen (PSA) blood test. Known as the Prostate Health Index (phi), the new test’s accuracy will effectively remove the need for many men who test positive for elevated PSA levels to undergo a biopsy to achieve a reliable diagnosis.

The PSA test is based on the fact that men with higher levels of the PSA protein are more likely to have prostate cancer,” said William Catalona, MD, PI of the Lurie Cancer Center’s Prostate Cancer SPORE. “The problem is that higher levels of PSA can also be caused by a benign enlargement or inflammation of the prostate, leading to many false-positives for cancer and ultimately unnecessarily invasive biopsies and an increased potential for patient harm.”

Because PSA testing isn’t conclusive enough on its own, physicians normally advise men with increased PSA levels in the range of 4-10ng/mL to undergo a prostate biopsy. However, the phi test helps physicians distinguish prostate cancer from benign conditions by utilizing three different PSA markers (PSA, FreePSA and p2PSA) as part of a sophisticated algorithm to more reliably determine the probability of cancer in patients with elevated PSA levels.

Because of the substantial increase in accuracy, results of a multi-center clinical study that Catalona led found a 31 percent reduction in unnecessary biopsies due to false-positives as a result of using the phi test.

Read more
CD73 Research Could Lead to Cancer Drug

BIN ZHANG, MD, PHD, Associate Professor of Medicine at the Feinberg School of Medicine, is among a group of international scientists awarded $8 million to attack cancer from multiple perspectives. Zhang is participating in a project targeting CD73, an enzyme that is overexpressed in many different forms of the disease. Although CD73 helps produce energy in cells, it can also suppress the immune system and allow tumor cells to reproduce.

“We are going to test an antibody that blocks this cancer-related pathway and reduces its ability to suppress the immune system,” said Zhang, a member of the Lurie Cancer Center. “Our previous findings show that many tumors highly express CD73, which limits anti-tumor immune responses, and that CD73 may serve as an emerging immune target for therapy.”

The study is part of the multinational TumAdoR project, which includes teams from Germany, Switzerland, France, Finland and the United States. The ambitious four-year investigation aims to produce an antibody that blocks a specific cancer pathway and have it ready for clinical trials by the end of the funding cycle.

Fighting Cancer Through Technology

WHEN YOU SEE your doctor for an annual physical, the routine is almost always the same: The doctor checks your blood pressure. Listens to your heart. Orders a few blood tests. But what if cancer screening became a part of that exam? And what if it were as simple as swiping the inside of your cheek with a cotton swab?

A breakthrough technology developed by Lurie Cancer Center member, Vadim Backman, PhD, the Water Dill Scott Professor in Biomedical Engineering at the McCormick School of Engineering, may make this screening a reality as soon as 2016. On February 26, Backman talked about the technology to a packed room in the Ford Center as part of the Farley Fellow Seminar Series, a lecture series that features entrepreneurial-minded faculty who share lessons learned while bringing ideas to market.

Nanocytology is “a combination of microscopy and spectroscopy, which is sensitive to cell morphology [at very low levels],” explained Backman, who co-founded Nanocytomics, the medical device company overseeing the nanocytology’s development and market launch. “It can see things that you otherwise couldn’t see under the microscope — things that are highly predictive of cancer.” Earlier cancer detection would mean earlier treatment — and, in the case of lung, colon or prostate cancer, could reduce mortality rates by approximately 50 percent.

In the fight against cancer, Backman has made financial and personal sacrifices to get both of his biomedical device companies off the ground. (Along with Nanocytomics, he is co-founder of AmeriOptics, which develops fiber-optic technology to identify patients at high risk for colorectal cancer.) But that drive, he says, is one of the central reasons why his entrepreneurial ventures have been a success: “If you want to create a biotech business that tries to solve a cancer problem, the last thing you want to think about is money,” he said. “I would argue that it should be about passion. If you’re passionate about it, it’s all going to work out.”

Bioinformatics and Computational Genomics Expert to Direct Cancer Informatics Core

RAMANA DAVULURI, PHD, a distinguished investigator in bioinformatics and computational genomics, joined the Lurie Cancer Center in February as Director of the Cancer Informatics Core Facility, and the Division of Health and Biomedical Informatics at the Feinberg School of Medicine, as Professor of Preventive Medicine and Neurological Surgery.

Davuluri’s interdisciplinary research is centered on developing statistically-rigorous data mining algorithms and informatics solutions, including those that promote an understanding of regulation and deregulation of genes at the isoform level. His current work also seeks to develop clinically-useful diagnostic tools for identifying specific subsets of brain tumor patients and subsequently directing appropriate therapeutic interventions. Davuluri has developed numerous bioinformatics software solutions for sequencing platforms.

“Analysis of big data from cancer genomics, proteomics and clinical trials requires smart data analysts with good computer programming skills and sound statistical knowledge,” said Davuluri. “Without the right skills, researchers will end up finding patterns that mean nothing and missing those that are gold. The core provides local expertise to develop and maintain state-of-the-art computational approaches for translating big data into clinically actionable patterns, and contribute to transforming basics science in practical benefits for cancer patients.”
Most People Would Share Data to Improve Healthcare

AN OVERWHELMING majority of study participants said they’d share information on their own well-being if the data was used to improve the future of healthcare. According to a new report co-authored by Lurie Cancer Center member Melissa Simon, MD, MPH, 94 percent of adult social media users with a health condition would allow for the dissemination of their health data—shared anonymously—to help clinicians improve care.

It’s important to note how overwhelming the response was,” said Simon, Vice Chair of Clinical Research in Obstetrics and Gynecology, Associate Professor of Preventive Medicine and Medical Social Sciences at the Feinberg School of Medicine. “As we move forward in the evolving healthcare delivery and research practice, there will need to be a significant investment in the creation of resources for data sharing and analysis, especially in the realm of big data.”

» Read more

Iron May be at Heart of Cancer Drug’s Cardiotoxicity Effect

THE ROLE iron plays in weakening a person’s heart following treatment with the common chemotherapy drug doxorubicin (DOX) has been revealed by Lurie Cancer Center member Hossein Ardehali, MD, PhD, Associate Professor in Cardiology and Pharmacology at Feinberg. Cardiomyopathy, a prevalent side effect of DOX, is dependent on the accumulation of iron inside the mitochondria of cells.

“When we started these experiments we thought the cardiomyopathy-doxorubicin link may have something to do with the mitochondria rather than the notion that the iron buildup was occurring in muscle cells as a whole,” said Ardehali, a member of the Feinberg Cardiovascular Research Institute. “Our investigations showed that to be true.”

Although heart damage remains the most serious side effect, DOX is commonly used in the treatment of a wide range of cancers. Moving forward, the lab will work to produce a drug that would specifically reduce mitochondrial iron to treat doxorubicin-induced cardiomyopathy. Ardehali’s group has already identified a number of potential compounds and is working in collaboration with the Center for Molecular Innovation and Drug Discovery (CMIDD) to begin preclinical trials.

» Read more...

Pathology Core Facility Launches New Website

A SHARED RESOURCE of the Lurie Cancer Center, the Pathology Core Facility (PCF) provides laboratory processing (histology, immunohistochemistry, molecular analysis and extraction, and microscopic evaluation); procurement of biospecimens for clinical trials and biobanking. It also serves as the coordinating office and reference laboratory for the ECOG-ACRIN Cancer Research Group.

Visit the new PCF website at pathcore.facilities.northwestern.edu to learn more about its ability to service biomarker research within Northwestern University and around the world.
Gius Named Interim Co-Leader, Women’s Cancer Research Program

DAVID GIUS, MD, PHD, has been named Interim Co-Leader of the Women’s Cancer Research Program at the Lurie Cancer Center, while a nationwide search to identify the next permanent leader of the program is ongoing. Gius, a nationally recognized radiation oncologist and researcher, is a Professor in Radiation Oncology at the Feinberg School of Medicine.

The Women’s Cancer Research Program (WCRP) embraces a multidisciplinary approach to integrate its basic, translational, and clinical components. The program seeks to define the common mechanisms responsible for the risk and progression of tumors arising from the reproductive tissues of women including the breast, ovary, endometrium, myometrium, uterine cervix and vagina. In doing so, the goals of the WCRP are to identify molecular markers that contribute to the disease process and outcome, to develop targeted molecular approaches, and to translate these agents from pre-clinical models to the bedside.

In collaboration with Co-Leader Seema Khan, MD, Gius will increase the WCRP’s translational research activity. “David is an outstanding researcher and physician scientist who has made major contributions in the field of breast cancer research. His research is of very high quality and has been consistently funded by the National Cancer Institute,” said Leonidas Platanias, MD, PhD, Interim Director of the Lurie Cancer Center.

» Read more

Remembering Lora Dequeredo

A LONG TIME and beloved member of the Lurie Cancer Center nursing family, Lora Dequeredo, passed away in January. Lora was a nurse clinician with Dr. William Gradishar’s team for over ten years. She was a phenomenal clinician whose compassion, charisma, and energetic personality deeply impacted her patients, her colleagues, and the entire Northwestern community. She will be sorely missed by all of us.

International Partnership to Focus on Nanomedicine

NORTHEASTERN UNIVERSITY’S International Institute for Nanotechnology (IIN) is collaborating with Nanyang Technological University (NTU) in Singapore to establish the NTU-Northwestern Institute for Nanomedicine. Both universities are putting in substantive investments in this multi-million dollar research institute that will focus on the medical application of nanotechnology.

The medical field is an area in which nanotechnology is expected to have the most profound impact and benefit to society, and the new institute is poised to realize significant advances. The NTU-Northwestern Institute for Nanomedicine will support a global group of scientists working on joint research projects in the areas of disease diagnostics, timed-release therapeutics and targeted drug delivery methods, which would greatly increase the efficacy of existing drugs.

Lurie Cancer Center members, Chad Mirkin, PhD, Director of the IIN, the George B. Rathmann Professor of Chemistry in the Weinberg College of Arts and Sciences and a scientific advisor to President Barack Obama, and Vinayak Dravid, PhD, IIN Director of Global Partnerships, the Abraham Harris Professor of Materials Science and Engineering in the McCormick School of Engineering and Applied Science and Director of Northwestern’s Atomic and Nanoscale Characterization Experimental Center, will lead the institute effort at Northwestern.

Lurie Cancer Center Patient Assistance Fund

THE LURIE CANCER CENTER’s Department of Supportive Oncology has assumed administrative responsibility for the Patient Assistance Fund, managing the disbursement of vouchers to support co-pay assistance, pharmacologic needs not covered by prescription coverage, and other issues that represent barriers to patient care.

These funds are intended to be “bridge” funds, and each application is evaluated by both clinical staff (social work) as well as administrative staff (Tim Pearman, Rebecca Caires, or Stacey Rogers). Typically they are able to handle requests within the same day, but there may be times when a request is not completed for up to 24 hours. Please contact Director of Supportive Oncology, Tim Pearman, PhD, at tpearman@nmff.org, with questions.
Awards & Honors

Zeeshan Ahmad Butt, PhD, Associate Professor in Medical Social Sciences at the Feinberg School of Medicine, received a Presidential Citation from the American Psychological Association (APA). Dr. Butt was recognized “for his scholarly contributions related to clinical health psychology and his remarkable ability to foster professional engagement and career development among early career health psychologists.”

John Galvin, MD, Instructor in Hematology/Oncology at Feinberg, received the 2014 Auxiliary Board Grant from the Northwestern Memorial Foundation for his research project, "Minor Histocompatibility Antigen-Coupled Microparticles for Treatment of an Experimental Model of Acute Graft-versus-Host Disease."

In addition, Galvin received a grant from the 2014 Mathews Endowment Fund for the research project, "Ex vivo expansion of human natural T-regulatory cells for the prevention of acute graft versus host disease." As the founder of Early Exposures, a program that works with community-based youth organizations to teach photography, Dr. Galvin was also a recipient of Northwestern’s Martin Luther King Jr. Humanitarian Award.

David Gius, MD, PhD, Professor in Radiation Oncology at Feinberg, was elected to the Northwestern University Chapter of Alpha Omega Alpha (AOA). Membership in AOA is synonymous with academic excellence, as well achievements in the areas of research, community service, and leadership.

Liming Li, PhD, Associate Professor in Molecular Pharmacology and Biological Chemistry at Feinberg, was named Chair of the Women Faculty Organization (WFO). Li previously served as co-chair of the organization.

Cancer Support Team Awards

Two teams received Cancer Support-Team Awards from the Lurie Cancer Center. These awards are made to support team-led projects related to the role of behavior in cancer prevention, control and/or survivorship outcomes. They must also address the underlying biological mechanisms that link the behavior and outcomes. Each team is required to include at least two investigators with expertise in different disciplines.

Sofia Garcia, PhD, and Sheetal Kircher, MD received an award for their project, Assessing Psychosocial Factors, Pro-Inflammatory and Pro-Angiogenic Cytokines in Patients with Newly Diagnosed Colorectal Cancer. Garcia is an Assistant Professor in Medical Social Sciences, and Kircher is an Assistant Professor in Hematology-Oncology at Feinberg.

David Victorson, PhD, Thomas McDade, PhD, and Emma Adam, PhD received support for their project, Integrating Stress Biomarkers into an Ongoing Randomized Clinical Trial of Mindfulness Meditation in Young Adults with Cancer Using Novel Collection Approaches. Victorson is an Associate Professor in Medical Social Sciences at Feinberg, McDade is a Professor in Anthropology at the Weinberg College of Arts & Sciences, and Adam is a Professor in Northwestern’s School of Education and Social Policy.
Awards & Honors

Lurie Clinical Cancer Center Awards

Recipients of the Lurie Clinical Cancer Center Awards celebrated with colleagues at an awards ceremony and reception on February 27.

2013 Clinical Cancer Center Medical Professional Award

Mary Koludrovic, LCSW, and Judy Pi, PharmD, BCOP, received the 2013 Medical Professional Award. This award was established in 2011 to recognize a clinical professional for their dedication, commitment, thoughtfulness and overall care of patients.

2013 Vicki Maurer Clinical Cancer Center Nursing Award

Kathy Ward, RN, BSN, and Rebekah Worden, RN, received the 2013 Vicki Maurer Clinical Cancer Center Nursing Award. Established in 2004, the donor of this award named it in honor of his nurse, Vicki Maurer, whom he felt exemplified hard work and compassion.

2013 JoAnn Jones Clinical Cancer Center Staff Support Award

Patricia Hernandez received the JoAnn Jones Clinical Cancer Center Staff Support Award for 2013, given to a support staff member for their knowledge, thoughtfulness, and overall care of patients. This award was established in 2008 in honor of former support staff employee JoAnn Jones, who demonstrated all of these qualities.

Compassionate Care Awards

The Compassionate Care Awards, sponsored annually by the Woman’s Board of Northwestern Memorial Hospital, recognizes a physician on the medical staff, a fellow or medical resident, and a nurse or allied health professional who exemplify compassionate care of patients at the Lurie Cancer Center.

Compassionate Care Award Recipients:

Emily Prendergast, MD, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology

Ryan Gentzler, MD, Department of Medicine, Division of Hematology/Oncology

Kristen Huber, MSW, LCSW, OSW-C, Department of Radiation Oncology, Supportive Oncology Program
Patient & Public Programs

THE LURIE CANCER CENTER is committed to educating the public about cancer prevention and treatment, and offers a wide range of community events and patient programs throughout the year. Below is a list of programs scheduled through April, 2014.

LEARN MORE AND REGISTER AT cancer.northwestern.edu or call 312.695.1390

Conversations About Colorectal Cancer

Saturday, March 8, 2014
Robert H. Lurie Medical Research Center, Baldwin Auditorium

This free program is an opportunity for patients and their families to learn about new treatment options and survivorship. A panel of experts from the Lurie Cancer Center will answer questions.

Lung Cancer Foundation Living Room Support Group

Tuesday, March 18, 2014
Streamed live online

Lurie Cancer Center member Malcolm DeCamp, Jr., MD, Chief of Thoracic Surgery at Northwestern Medicine, will discuss minimally invasive surgical techniques for lung cancer diagnosis, staging and treatment. The Bonnie J. Addario Lung Cancer Foundation’s Living Room, the nation’s premier online lung cancer support group for lung cancer patients and their families, will be streamed live online from 7:30 – 9:30 p.m. (CT) at http://www.lungcancerfoundation.org/patients/support/

Cancer Connections

Saturday, March 22, 2014
Feinberg Pavilion, 3rd Floor, Conference Room A

Offered quarterly, this educational event is dedicated to improving the quality of life for patients, their families and caregivers—during and after cancer treatment. In addition to workshops on a wide range of topics, the program offers a chance to discover integrative therapies, networking groups, and peer support programs. This program is open to the public and to health care providers.

MEN Patient Seminar

Saturday, March 22, 2014
Feinberg Pavilion, 3rd Floor, Conference Room A

Multiple endocrine neoplasia patients and their families are invited to this half-day educational seminar presented by the Lurie Cancer Center in partnership with American Multiple Endocrine Neoplasia Support. Participants are encouraged to attend the Cancer Connections program offered that morning.

"Night of Humor and Healing" for Young Adult Cancer Survivors

Wednesday, April 9, 2014
The Second City Comedy Club

The evening includes a one-hour improv show, refreshments, and an opportunity for adolescent and young adult cancer survivors (16-40 years of age) to connect. Author, comedian, and four-time cancer survivor, Glenn Rockowitz, is the special guest speaker.
Fundraising Events

Dancing With Chicago Celebrities
Friday, March 7, 2014
Hyatt Regency Chicago

Virginia Kaklamani, MD, DSc, is adding dancer to her long list of accomplishments, participating in this annual benefit to raise funds for breast cancer research at the Lurie Cancer Center and Northwestern Medicine.

Rock Out Melanoma: Battle of the Bands
Saturday, March 8, 2014
Field’s Volvo, Northfield

An evening of music and dancing to help Skin of Steel support the National Melanoma Tissue Bank at the Lurie Cancer Center.

Big Ed Bowl
Tuesday, March 25, 2014
Lucky Strike Lanes, Chicago

Help strike out cancer! Funds raised support melanoma research at the Lurie Cancer Center.

The Carol Gollob Foundation’s “Swinging for a Cure”
Saturday, April 19, 2014
Midtown Tennis Club, Chicago

An evening of tennis, food and good company, the Chicago Charity Tennis Clinic benefits breast cancer research at the Lurie Cancer Center.

Chicago Spring Half Marathon / 10K
Saturday, May 18, 2014
The Park at Lakeshore East, Chicago

The races and celebration support vital programs and research at the Northwestern Brain Tumor Institute (NBTI).
THROUGHOUT THE YEAR, the Lurie Cancer Center offers professional education on various cancer related topics. Below is a list of programs scheduled through November 2013.

LEARN MORE AND REGISTER AT cancer.northwestern.edu or call 312.695.1391

Gastrointestinal Malignancies: 2014 Update of Clinical Care

March 7, 2014
Feinberg Pavilion, Conference Room A
Chair: Mary Mulcahy, MD

Malkin-Kraft Lectureship: New Roles for the RB Tumor Suppressor

March 18, 2014
Lurie Medical Research Center, Hughes Auditorium
Speaker: Jacqueline Lees, PhD
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology

MDS/MPN Rounds

Wednesday, March 18, 2014
UIC Forum, Chicago
Speaker: Brady Stein, MD

Protein-Protein Interactions: A Promising Avenue for Drug Discovery Symposium

March 19, 2014
Lurie Medical Research Center, Baldwin Auditorium
Speaker: Andrew Binkowski, PhD
Argonne National Laboratory

Hosted by the Center for Molecular Innovation and Drug Discovery

Grand Rounds & Tumor Cell Biology

GRAND ROUNDS

Fridays: 8:00 a.m. to 9:00 a.m.
Robert H. Lurie Medical Research Center
303 E. Superior, Chicago
Gray Conference Room (unless otherwise noted)

Presented by the Division of Hematology/Oncology and the Lurie Cancer Center, the weekly Grand Rounds update physicians and healthcare personnel on developing trends and techniques in medicine.

> Schedule at cancer.northwestern.edu/grandrounds

TUMOR CELL BIOLOGY

Thursdays: 1:00 p.m. to 2:00 p.m.
Robert H. Lurie Medical Research Center
303 E. Superior, Chicago
Baldwin Auditorium (unless otherwise noted)

The Tumor Cell Biology Seminars present weekly updates on novel translational cancer research in the areas of tumor biology, biomedical informatics and cancer prevention and diagnosis.

> Schedule at cancer.northwestern.edu/tcb

If you would like to receive weekly reminders about the Grand Rounds and/or TCB Seminar schedules please contact Denise Marshall at d-marshall4@northwestern.edu.

Cancer & Fertility Virtual Grand Rounds

The Oncofertility Consortium has created a series of Virtual Grand Rounds, primarily for the clinical community, to increase reproductive education among oncology and reproductive providers. Learn more about how specific chemotherapeutic drugs and radiation treatments used to treat brain cancer, can impact fertility. Providers can also get information about the latest fertility preservation options, get access to reproductive specialists in their region, and receive free CME credits through this program, which is accessible via computer or mobile device.

Illinois oncology providers interested in connecting with other providers and reproductive specialists in the Illinois area can participate in the Consortium’s pilot program to increase oncofertility communication and education.

E-mail Brigid Martz at brigid.martz@northwestern.edu or call her at 312.503.2506 to learn more.

> View the Oncofertility Virtual Grand Rounds Schedule at http://oncofertility.northwestern.edu/media?tid5=33
Funding Opportunities

Travel Grants

Katten Muchin Rosenman Travel Scholarship Program

The Katten Muchin Rosenman Travel Scholarship Program allows doctoral students and postdoctoral fellows to present the results of their basic cancer research.

Center for Genetic Medicine Travel Fellowship

The Center for Genetic Medicine (CGM) Travel Fellowship allows doctoral students and postdoctoral fellows to present the results of their basic cancer research showing its genetics relevance.

Cancer Prevention and Control Travel Scholarship Program

The Cancer Prevention Travel Scholarship Program allows doctoral students and postdoctoral fellows to present the results of their laboratory, clinical, population or behavioral research with implications for cancer prevention.

Deadline: July 11, 2014

» Details and application here

Basic Sciences Research Division

H Foundation Incentive Awards provide funding for faculty who have submitted and received a score on a RO1 grant to the NCI for the first time in their career. If additional funds are available, awards will be made to other faculty for new, first-time NCI RO1 submissions, which are scored but not yet funded.

H Foundation Bridge Awards provide up to $20,000 of support for competing renewals of NCI-sponsored RO1 research that missed the payline.

Applications for H Foundation Incentive and Bridge Awards are reviewed on a rolling basis and accepted until funds for the year are expended.

» Details and application here

Lea Charitable Trust Equipment Grants

Through the generous support of the Lea Charitable Trust, a pool of funds is available to full members of the Lurie Cancer Center affiliated with one of the Basic Sciences Research Programs for use by multiple investigators or to support small equipment grants for collaborative research projects.

Lea Charitable Trust Equipment Grants are made on a rolling basis as funds become available.

» Details and application here

Big Ten Cancer Research Consortium Applications for Oncology Trial Concepts

The Big Ten Cancer Research Consortium (BTCRC) is actively seeking concepts for highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. The BTCRC is setting the goal to receive at least one new concept from each institution during 2014.

Once submitted, concepts will be discussed through a clinical trial working group mechanism. These disease-specific working groups are another way to increase collaboration across the BTCRC institutions and provide an opportunity for senior investigators to mentor junior investigators throughout the development of these translational trials.

Concepts will be accepted on an ongoing basis throughout the year.

» Details & application here

Cancer Health Disparities Summer Research Program

The Cancer Health Disparities Research Program, part of the NU NEIGHBORS’ Partnership between the Lurie Cancer Center and Northeastern Illinois University (NEIU), is an 8-week summer program offered at the Lurie Cancer Center. The program will be offered to NEIU undergraduate students interested in pursuing careers in the social sciences and health care. The application deadline is April 14, 2014.

» Details and application here
Welcome
New Staff

NEW STAFF

Bryan Breau
Regulatory Coordinator
Clinical Research Office
b-breau@northwestern.edu

Carolyn Passaglia
Manager of Research Operations
Clinical Research Office
c-passaglia@northwestern.edu

Ingrid Fowler-Wrather
Associate Research Administrator
Business Operations
i-fowler@northwestern.edu

Yekaterina Sigalova
Regulatory Coordinator
Clinical Research Office
y-sigalova@northwestern.edu

Cionne Manning
Research Project Coordinator
Clinical Research Office
cionne.manning@northwestern.edu

Stephanie Terns
Clinical Research Coordinator
Clinical Research Office
s-rindt@northwestern.edu

Lurie Cancer Center
Office of Public Affairs and Communications
676 N. St. Clair
Suite 1200
Chicago, IL 60611
312.695.1304

Interim Director
Leonidas Platanias, MD, PhD
Director,
Public Affairs and Communications
Sharon Markman
Interim Associate Director, Administration
Matthew Ruchin
Managing Editor
Jennifer Bowker

Help Wanted:
Reporters

PLEASE SEND SUGGESTIONS for this newsletter to Jennifer Bowker,
j-bowker@northwestern.edu

Join Our Mailing List

Sign up to have news from the Lurie Cancer Center for oncology professionals delivered to your inbox. Email Jennifer Bowker at j-bowker@northwestern.edu

WHAT’S NEW

IT Support Contact Information

A new contact procedure is in place for IT support. Please be sure to provide complete information when entering requests (i.e. office #, location, detailed issue information), since many departments throughout the medical school use this same system. The new contact information is:

Feinberg Information Technology
fsmhelp@northwestern.edu
847-491-HELP (Option 5)

Lurie Cancer Center Weekly Updates

INFORMATION TO BE CONSIDERED for inclusion in the Lurie Cancer Center’s weekly e-mail updates must be received at least one week in advance. Submit suggestions to Denise Marshall at d-marshall4@northwestern.edu.